These findings indicate that combined curcumin and doxorubicin induce apoptosis primarily through JNK-dependent MAPK signaling, accompanied by stress-associated cellular responses.

Moreover, they effectively promote CRT exposure, HMGB1 release, and ATP secretion in 4T1 cells. Furthermore, in a murine breast cancer model, CMCS-D + C/NPs significantly upregulate the expression of proteins such as CD8 and Caspase-3, cytokines (IFN-γ and IL-6), and Granzyme B, demonstrating favorable antitumor efficacy.

P1, N=42, Completed, APR Applied Pharma Research s.a. | Not yet recruiting --> Completed | N=100 --> 42

In vivo studies confirmed that treatment with Utt-B mitigates the development of primary hepatic tumors in an orthotopic xenograft model and impedes the pulmonary metastasis of HCC in a murine metastasis model, via the down-regulation of EGFR/ERK axis. Taken together, the current findings attest to the exceptional therapeutic potential of Utt-B against primary and metastatic HCC and highlight its potential as a candidate drug to be evaluated in the clinics for the benefit of HCC patients having limited prognosis and therapeutic options.

Molecular docking analyses supported the binding of CUR and DOX to key ferroptosis regulators. This study shows the potential of CUR to sensitize DOX-resistant cancer cells through ferroptosis-linked-oxidative stress targeting.

A combination of defactinib and the MDM2 inhibitors showed that nutlin-3a showed synergistic/additive effects in wild-type and antagonistic effects in mutated TP53 cells, whereas RITA retained synergistic activity in mutated TP53 cells. These results suggest that the therapeutic success of combined FAK and MDM2 inhibition in mesothelioma depends on the precise matching of MDM2 inhibitors with the TP53 genotypes, and highlight the need for genotype-based selection of MDM2 inhibitors.

P1/2, N=75, Recruiting, Oncorena AB | Trial completion date: May 2027 --> Dec 2027 | Trial primary completion date: May 2027 --> Dec 2027

P1, N=15, Recruiting, Keystone Nano, Inc | Enrolling by invitation --> Recruiting | Trial completion date: Oct 2027 --> Nov 2026 | Trial primary completion date: Feb 2027 --> Sep 2026

Our discovery of Utt-B, a phytosaponin that exhibits remarkable anti-HCC potential and is a United States FDA-designated orphan drug against HCC, has gained global recognition. The present study reveals Utt-B as a propitious candidate drug against MASH and MASH-induced HCC in a high-fat diet murine model and streptozotocin-induced steatohepatitis-derived HCC animal model, respectively.

Compared with the inhibitor group, the serum level of IL-6, the contents of 4-HNE and MDA, and protein expression of p53 in colonic tissue in the activator group were elevated (P<0.05), while the body weight, the contents of SOD and GSH, and protein expression of GPX4 in colonic tissue were reduced (P<0.05). Moxibustion at "Tianshu" (ST25) could alleviate intestinal inflammation in CD mice, possibly by downregulating the protein expression of p53, enhancing the activity of the SLC7A11/GSH/GPX4 pathway, reducing the production of lipid peroxides, maintaining intestinal iron homeostasis, and reducing colonic ferroptosis.

P1/2, N=75, Recruiting, Oncorena AB | Trial completion date: Aug 2025 --> May 2027 | Trial primary completion date: Feb 2025 --> May 2027 | N=50 --> 75

ACOX3 represents a dual diagnostic and prognostic biomarker with broad pan-cancer relevance, exhibiting distinct immune correlates and therapeutic potential.